# Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer

> **NCT05385900** · NA · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Penpulimab combination with anlotinib and chemotherapy

## Key facts

- **NCT ID:** NCT05385900
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2022-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385900, "Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT05385900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*